# Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

> **NCT02323607** · PHASE1 · COMPLETED · sponsor: **Bhavana Bhatnagar** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02323607
- **Lead sponsor:** Bhavana Bhatnagar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-12
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-07-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323607, "Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02323607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*